Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Multiple Dose Study to Investigate the Pharmacokinetics of Omecamtiv Mecarbil Administered Orally to Patients With Stable Heart Failure

Next Previous
Trial Profile

An Open Label, Multiple Dose Study to Investigate the Pharmacokinetics of Omecamtiv Mecarbil Administered Orally to Patients With Stable Heart Failure

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omecamtiv mecarbil (Primary)
  • Indications Heart failure
  • Focus Pharmacokinetics
  • Sponsors Cytokinetics

Most Recent Events

  • 27 May 2011 Planned end date changed from 1 Oct 2011 to 1 May 2011 as reported by ClinicalTrials.gov
  • 27 May 2011 Status changed from suspended to withdrawn prior to recruitment as reported by ClinicalTrials.gov
  • 30 Sep 2010 Planned end date changed from 1 May 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top